Novel Imaging Model Helps Reveal New Therapeutic Target for Pancreatic Cancer

Antisense treatment in preclinical models shows effectiveness against deadly tumors —

Pancreatic ductal adenocarcinoma, the most common of pancreatic cancers, is extraordinarily lethal, with a 5-year survival rate of just 6 percent. Chemotherapy treatments are poorly effective, in part due to a high degree of drug-resistance to currently used regimens.

In a new study, published online June 6 in Nature, researchers at University of California San Diego School of Medicine and Moores Cancer Center, together with colleagues at Keio University, the University of Nebraska and Ionis Pharmaceuticals describe an innovative new model that not only allowed them to track drug resistance in vivo, but also revealed a new therapeutic target … Read the Full Story from the UC San Diego Newsroom

Tannishtha Reya, PhD, Professor of Medicine in the Division of Hematology-Oncology and Professor of Pharmacology, was co-principal investigator of the project.

Dr. Frederick D. Park

Dr. Frederick D. Park

Another Department of Medicine coauthor was Frederick D. Park, MD, PhD, Assistant Professor in the Division of Gastroenterology.

UC San Diego Health Researchers Join Pancreatic Cancer “Dream Team”

November 10, 2015

International effort will seek to develop and test new therapies for deadly malignancy —

In an effort to advance research on one of the deadliest forms of cancer, University of California, San Diego School of Medicine researchers Andrew Lowy, MD, and Tannishtha Reya, PhD, have been recruited for their expertise in preclinical modeling, clinical trials and stem cell biology to join a “dream team” of international pancreatic cancer researchers.

The three-year, $12-million effort, sponsored by Stand Up To Cancer, Cancer Research UK and The Lustgarten Foundation, will pursue a three-pronged strategy to better understand and reset so-called “super-enhancers” that may be abnormally active in pancreatic tumors. Super-enhancers are bits of DNA that can cause over-expression of genetic signals, fueling cancer cell growth. … Read the full story from the UC San Diego Newsroom

Tannishtha Reya, PhD, is Professor of Pharmacology in the Skaggs School of Pharmacy and Pharmaceutical Sciences and Professor of Medicine in the University of California, San Diego School of Medicine.

Split Decision: Stem Cell Signal Linked With Cancer Growth

Researchers at the University of California, San Diego School of Medicine have identified a protein critical to hematopoietic stem cell function and blood formation. The finding has potential as a new target for treating leukemia because cancer stem cells rely upon the same protein to regulate and sustain their growth. … Read the full story from the UC San Diego News Center

Dr. Gary HardimanGary Hardiman, PhD, associate professor in the Division of Endocrinology and Metabolism, is an investigator on the study.

Citation for the study report in Nature Genetics: Bryan Zimdahl, Takahiro Ito, Allen Blevins, Jeevisha Bajaj, Takaaki Konuma, Joi Weeks, Claire S Koechlein, Hyog Young Kwon, Omead Arami, David Rizzieri, H Elizabeth Broome, Charles Chuah, Vivian G Oehler, Roman Sasik, Gary Hardiman & Tannishtha Reya. Nature Medicine advance online publication, 02 February 2014 (doi:10.1038/ng.2889). Summary | Full text (UCSD only)